PPIs Linked to Lower Cancer Risk in Barrett's Esophagus-- Eric Metcalf
Monday, December 28, 2009
MONDAY, Dec. 28 (HealthDay News) -- Patients with Barrett's esophagus who take proton pump inhibitors (PPIs) have a lower risk of high-grade dysplasia and esophageal cancer, according to research published in the December issue of Clinical Gastroenterology and Hepatology.
Dang M. Nguyen, M.D., of the Michael E. DeBakey Veterans Affairs Medical Center in Houston, and colleagues analyzed data from 344 patients, mostly male and with a mean age of 61 years, who were diagnosed with Barrett's esophagus. During follow-up, 33 patients developed high-grade dysplasia or esophageal adenocarcinoma.
In multivariable analysis, the researchers found that prescriptions for PPIs were associated with a 61-percent lower risk of high-grade dysplasia or esophageal adenocarcinoma. Prescriptions for nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin were associated with a non-significant trend toward lower incidence of these outcomes. Statin prescriptions, however, weren't associated with the development of dysplasia or cancer.
"In conclusion, this cohort study suggests that PPI therapy may reduce the incidence of high-grade dysplasia or esophageal adenocarcinoma in patients with Barrett's esophagus. NSAIDs/aspirin may also have a role as chemopreventive agents in Barrett's esophagus. Ongoing randomized controlled trials such as the Aspirin Esomeprazole Chemoprevention Trial may provide more insight into the role of PPI and NSAID as chemoprevention agents in Barrett's esophagus," the authors conclude.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.
May 28, 2014
November 25, 2015